N@N

SuperGen Pipeline Presentations at EORTC-NCI-AACR

^{Published on 2010-11-15 04:45:27 - Market Wire}
 

DUBLIN, Calif.--([ BUSINESS WIRE ])--SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts detailing recent work with SuperGen compounds. Poster presentations by SuperGen and collaborators will occur on November 17 and 19, 2010 at the 2010 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

The presentations will review pre-clinical advances in amuvatinib (MP-470) and SGI-110. The posters will be made available for viewing on the companya™s website [ www.supergen.com ] following the respective presentations.

amuvatinib (MP-470): Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with Etoposide (VP-16) in Small Cell Lung Cancer (SCLC) cell lines and xenografts
Abstract 171, Poster 128
Poster Presentation: Wednesday Nov 17, 12:00 a" 2:20 pm CET

amuvatinib (MP-470): Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines
Abstract 193, Poster 150
Poster Presentation: Wednesday Nov 17, 12:00 a" 2:20 pm CET

SGI-110: Immunomodulatory activity of SGI-110, a 5-aza-2a™deoxycytidine-containing demethylating dinucleotide
Abstract 547, Poster 083
Poster Presentation: Friday Nov 19, 8:00 a" 9:30 am CET

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit [ http://www.supergen.com ].